GlobalData Plc

Unmet needs in the rheumatoid arthritis space, which is set to reach a value of $28.5 billion by 2025, are not expected to be directly addressed by pipeline agents over the next few years, according to GlobalData, a recognized leader in providing business information and analytics.

The company’s latest report states that the disease is effectively treated by currently available options, and upon launch, pipeline agents will compete for the same patient populations. Although drugs with novel mechanisms of action are welcome additions to the market, the real challenge will be to determine where these drugs fit into the treatment paradigm.

Kavita Rainova, MSc, Senior Healthcare Analyst at GlobalData, explains: “Unmet needs, including the need for personalized treatments and earlier diagnosis, are likely to be met through initiatives and research efforts to understand the pathophysiology of rheumatoid arthritis, and through the development of diagnostic and prognostic biomarkers for the disease.

“While research in this area is underway, it is expected that individualized medicine will still be in its beginning stages by the end of the forecast period in 2025.”

With ongoing research in biomarker discovery, it is likely that subsets of rheumatoid arthritis patients will be described at a molecular level, which is expected to have major implications in the treatment of the disease, and may even assist physicians in making informed decisions about tapering off medications.

Rainova continues: “Drug developers should be aware of the ongoing trend of tapering off medications. As biologics are so expensive, patients and physicians must often work together to find a regimen that works best for the patient. This may involve taking drugs less frequently or even stopping therapy altogether if the patient has responded well and no longer has active disease.

“The frequency of dosing is often taken into account with regard to drug pricing. For example, Simponi is more expensive per injection than Enbrel, as Simponi is taken only once for every four injections of Enbrel. Drug developers should account for drug tapering in their pricing strategy, and possibly even consider offering rebates for qualified patients as a financial incentive for those who cannot afford these medications.”

– Information based on GlobalData’s report: PharmaPoint: Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2025.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF